

Food and Drug Administration (FDA)
Center for Biologics Evaluation and Research (CBER)
Office of Vaccines Research and Review
183rd Meeting of the Vaccines and Related Biological Products
Advisory Committee
October 5, 2023
AGENDA

Topic: Strain Selection for the Influenza Virus Vaccines for the 2024 Southern Hemisphere Influenza Season

Time	Presentation/Presenter
8:30 a.m.	<p><u>Opening Remarks: Call to Order (10 Min)</u></p> <ul style="list-style-type: none"> • Hana El Sahly, M.D. Chair, VRBPAC Professor, Department of Molecular Virology and Microbiology Baylor College of Medicine <p><u>Administrative Announcements, Roll Call, Conflict of Interest Statement (20 Min)</u></p> <ul style="list-style-type: none"> • Sussan Paydar, Ph.D. Designated Federal Officer, VRBPAC Division Of Scientific Advisors and Consultants, CBER, FDA
9:00 a.m.	<p><u>Introduction – 2024 Southern Hemisphere Influenza Virus Vaccine Strain Selection (15 Min total)</u></p> <ul style="list-style-type: none"> • Jerry Weir, Ph.D. (10 Min) Director Division of Viral Products Office of Vaccines Research and Review (OVRP) CBER, FDA • Q & A – 5 Min
9:15 a.m.	<p><u>Global Influenza Virus Surveillance and Characterization (70 Min total)</u></p> <ul style="list-style-type: none"> • David Wentworth, Ph.D. (55 min) Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza

	<p>Director, Coronavirus and Other Respiratory Viruses Division (CORVD) Centers for Disease Control and Prevention</p> <ul style="list-style-type: none"> • Q & A – 15 Min
10:25 a.m.	BREAK (10 Min)
10:35 a.m.	<p>Challenges and Opportunities for Vaccine Strain Composition with the Reduced Public Health Threat from Influenza B/Yamagata Lineage Viruses (45 Min total)</p> <ul style="list-style-type: none"> • Comments from Manufacturers Representative (15 Min) David Greenberg, M.D. Global Senior Expert Medical Strategy, Vaccines Sanofi • FDA Perspective (15 Min) Jerry Weir, Ph.D. Director Division of Viral Products Office of Vaccines Research and Review (OVRP) CBER, FDA • Q & A – 15 min
11:20 a.m.	Open Public Hearing (OPH) (60 Min)
12:20 p.m.	Committee Discussion, Recommendations and Voting (70 Min)
1:30 p.m.	Adjourn Meeting - DFO